Stoke Therapeutics, Inc. (STOK)

NASDAQ: STOK · IEX Real-Time Price · USD
8.30
+0.13 (1.59%)
At close: Mar 21, 2023, 4:00 PM
8.39
+0.09 (1.08%)
After-hours: Mar 21, 2023, 6:02 PM EDT
1.59%
Market Cap 366.43M
Revenue (ttm) 12.41M
Net Income (ttm) -101.07M
Shares Out 44.15M
EPS (ttm) -2.60
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 346,044
Open 8.21
Previous Close 8.17
Day's Range 8.10 - 8.58
52-Week Range 6.88 - 25.44
Beta 0.42
Analysts Buy
Price Target 33.76 (+306.75%)
Earnings Date May 9, 2023

About STOK

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output to design ASOs to precisely upregulate protein expression. Its lead clinical candidate is STK-001, which is in phase I/IIa clinical trial to treat Dravet syndrome, a severe and progressive genetic epilepsy; and STK-002, which is in preclinical stage for the treat... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 19, 2019
Employees 102
Stock Exchange NASDAQ
Ticker Symbol STOK
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 17 analysts, the average rating for STOK stock is "Buy." The 12-month stock price forecast is $33.76, which is an increase of 306.75% from the latest price.

Price Target
$33.76
(306.75% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet Syndrome

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit...

6 days ago - Business Wire

Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 9.72% and 11.42%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the st...

2 weeks ago - Zacks Investment Research

Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit...

2 weeks ago - Business Wire

Stoke Therapeutics to Participate at Upcoming March Investor Conferences

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit...

3 weeks ago - Business Wire

Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference

Stoke Therapeutics to Present at the SVB Securities Global Biopharma Conference

1 month ago - Business Wire

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression w...

2 months ago - Business Wire

Nuvig Therapeutics Appoints Julie Smith Chief Executive Officer

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, today announced the ...

Other symbols: EXEL
2 months ago - Business Wire

Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression w...

2 months ago - Business Wire

Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual Meeting

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression w...

3 months ago - Business Wire

Stoke Therapeutics to Present Data from the Company's Dravet Syndrome Program at the American Epilepsy Society 2022 Annual Meeting

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression w...

4 months ago - Business Wire

Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 4.35% and 2.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the st...

4 months ago - Zacks Investment Research

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression w...

4 months ago - Business Wire

Is a Surprise Coming for Stoke Therapeutics (STOK) This Earnings Season?

Stoke Therapeutics (STOK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

4 months ago - Zacks Investment Research

Stoke Therapeutics, Inc. (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

After losing some value lately, a hammer chart pattern has been formed for Stoke Therapeutics, Inc. (STOK), indicating that the stock has found support. This, combined with an upward trend in earnings...

4 months ago - Zacks Investment Research

Moore Kuehn, PLLC Encourages Investors of Stoke Therapeutics, Inc. to Contact Law Firm

NEW YORK , Oct. 18, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street , is investigating whether certain officers and directors of Stoke Therapeutics, Inc. (NASDAQ: ...

5 months ago - PRNewsWire

Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit...

7 months ago - Business Wire

How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 91%

The average of price targets set by Wall Street analysts indicates a potential upside of 90.7% in Stoke Therapeutics, Inc. (STOK). While the effectiveness of this highly sought-after metric is questio...

7 months ago - Zacks Investment Research

7 Stocks Due for a Stunning Short Squeeze

Although the general rule of thumb is to avoid equities with heavy short interest, the new normal has brought with it new paradigms. One of these fresh approaches urges speculators to acquire short-sq...

Other symbols: LMNDMVISSANASIENTTCFWE
8 months ago - InvestorPlace

Stoke Therapeutics, Inc. (STOK) Reports Q2 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) delivered earnings and revenue surprises of 10% and 19.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

8 months ago - Zacks Investment Research

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit...

8 months ago - Business Wire

Stoke Therapeutics to Present at the 2022 Jefferies Healthcare Conference

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit...

10 months ago - Business Wire

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit...

11 months ago - Business Wire

Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit...

11 months ago - Business Wire

Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual Meeting

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression wit...

1 year ago - Business Wire